No profile data available.
Palvella Therapeutics, Inc. (PVLA) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Wayne, United States, with about 29 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$41.72 million. Its market capitalization was $2.00 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. 9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Palvella Therapeutics reported $0 in revenue for fiscal year 2025.
$2.00 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include United Therapeutics Corporation (UTHR), Liquidia Corporation (LQDA), Mineralys Therapeutics, Inc. (MLYS), Gossamer Bio, Inc. (GOSS).